University of Chicago
Pathology residency · Chicago, IL · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Chicago's research in pathology, which the program shares with other departments and affiliated hospitals.
About University of Chicagoinstitution-wide pathology research
Pathology publications from University of Chicago and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
51
works per year
27th of 65 pathology residency programs
-3.8%
2-year growth
44th of 65 pathology residency programs
21.9%
in top 10% of field (works before 2025)
18th of 56 pathology residency programs
43.8%
cited above world average
19th of 56 pathology residency programs
Works per year · * 2026 so far
Pathology and Forensic Medicine · 271
Pathology research topics at University of Chicago
Papers in the window; each links to the list on OpenAlex.
Most cited at University of Chicago since 2024
All pathology papers there on OpenAlex
- The Lancet Breast Cancer CommissionCharlotte Elizabeth Coles et al. · The Lancet · 2024 · PubMed · cited 199
- Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer Leigh Crombie et al. · Blood · 2024 · PubMed · cited 159
- Germline CDH1 Variants and Lifetime Cancer RiskCarrie E. Ryan et al. · JAMA · 2024 · PubMed · cited 73
- Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).Frank A. Sinicrope et al. · Journal of Clinical Oncology · 2025 · cited 59
- Phosphatidylethanol in steatotic liver diseaseNikolaj Torp et al. · Journal of Hepatology · 2025 · PubMed · cited 46
- Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamabTaylor Brooks et al. · Blood · 2025 · PubMed · cited 45
- Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C. Rutherford et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 36
- Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trialAmitkumar Mehta et al. · Blood Advances · 2024 · PubMed · cited 36
- Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseSravya Tumuluru et al. · Blood · 2025 · PubMed · cited 33
- Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic MechanismsMarta Włodarczyk et al. · Nutrients · 2024 · PubMed · cited 31